Advertisement

 

 

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.
Author Information (click to view)

Hung MH, Chen KF,


Hung MH, Chen KF, (click to view)

Hung MH, Chen KF,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert opinion on therapeutic targets 2017 06 0621(7) 685-694 doi 10.1080/14728222.2017.1336226
Abstract
INTRODUCTION
SET is a multitask oncoprotein that promotes the initiation and progression of cancer. Overexpression of SET has been characterized as being tumor-specific and is associated with adverse clinical outcomes in many different human malignant diseases. Notably, SET has been shown to promote the development of therapeutic resistance in cancer cells. Area covered: In this review, we summarized the currently available evidence relating to the oncogenic roles, biological functions and clinical relevance of SET protein in cancer. The anti-cancer effects of three different SET antagonists undergoing preclinical investigation are also discussed. Expert opinion: Emerging evidence supports the critical role of SET in regulating various different cancer hallmarks. Targeting the SET-associated protein interfaces may be a potential anti-cancer strategy for future development. However, more studies are required to clarify the best strategy to combine SET antagonists with other anti-cancer treatments and to explore possible biomarkers that predict responsiveness.

Submit a Comment

Your email address will not be published. Required fields are marked *

7 + 10 =

[ HIDE/SHOW ]